9,113 Shares in Genmab A/S (NASDAQ:GMAB) Purchased by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 9,113 shares of the company’s stock, valued at approximately $273,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. NewEdge Wealth LLC boosted its holdings in shares of Genmab A/S by 50.7% during the fourth quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock worth $3,820,000 after acquiring an additional 40,382 shares during the period. SG Americas Securities LLC boosted its stake in shares of Genmab A/S by 360.5% in the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock valued at $882,000 after buying an additional 23,094 shares during the period. Harding Loevner LP raised its position in Genmab A/S by 2.7% during the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after purchasing an additional 85,665 shares in the last quarter. Capital International Investors raised its position in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after purchasing an additional 315,355 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Genmab A/S by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock valued at $154,000 after purchasing an additional 3,770 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Up 0.4 %

Shares of NASDAQ:GMAB traded up $0.10 during mid-day trading on Monday, reaching $28.48. The company had a trading volume of 706,324 shares, compared to its average volume of 585,503. The firm has a market cap of $18.84 billion, a price-to-earnings ratio of 23.61, a PEG ratio of 1.01 and a beta of 0.97. The company’s 50-day moving average price is $27.03 and its 200-day moving average price is $28.38. Genmab A/S has a one year low of $24.53 and a one year high of $41.58.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The company had revenue of $603.30 million during the quarter, compared to analyst estimates of $594.23 million. On average, research analysts anticipate that Genmab A/S will post 1.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Truist Financial upped their price target on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, July 18th. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Finally, BTIG Research lifted their price objective on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $49.50.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.